 |
First Patients Enrolled In MIV Therapeutics VESTASYNC II Study (Medical News Today) |
MIV Therapeutics, Inc. (OTCBB: MIVT) (Frankfurt: MIV), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announces that the first patients have been enrolled in the registration trial of its VESTAsync™ polymer-free drug-eluting stent.
More: continued here
This entry was posted on Friday, May 23rd, 2008 and is filed under POLYMER. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Leave a comment